The scientist’s investigation covers issues in Epitope, Major histocompatibility complex, Immunology, Cytotoxic T cell and Molecular biology. His research integrates issues of Biochemistry, Peptide, Peptide sequence, Human leukocyte antigen and CTL* in his study of Epitope. Major histocompatibility complex is a subfield of Antigen that he investigates.
His Immunology study incorporates themes from Transplantation and Graft-versus-host disease. Victor H. Engelhard combines subjects such as Immune tolerance and Cell biology with his study of Cytotoxic T cell. His Molecular biology study combines topics in areas such as Antigen processing, MHC class I, Antigen presentation, Transporter associated with antigen processing and Tyrosinase.
Victor H. Engelhard mainly focuses on Immunology, Cytotoxic T cell, Antigen, Major histocompatibility complex and Molecular biology. His biological study spans a wide range of topics, including Cancer research, Virology and Cell biology. His research in Antigen intersects with topics in Cancer, Phosphopeptide, Antigen presentation and T-cell receptor.
He has included themes like CD8 and Peptide in his Major histocompatibility complex study. His Molecular biology study integrates concerns from other disciplines, such as Peptide sequence, Monoclonal antibody and Transporter associated with antigen processing. The CTL* study which covers Epitope that intersects with Human leukocyte antigen and Minor histocompatibility antigen.
Immunology, Cancer research, T cell, Antigen and Immune system are his primary areas of study. The study incorporates disciplines such as Phenotype, Internal medicine and Human melanoma in addition to Immunology. His Cancer research research incorporates elements of Inflammation, Chemokine, Cytotoxic T cell and Cancer immunotherapy.
His Cytotoxic T cell research includes elements of Tumor microenvironment, CD8, Lymph node, Cell biology and Naive T cell. His work in Major histocompatibility complex and Tolerance induction is related to Antigen. His Major histocompatibility complex research integrates issues from Cancer cell and T-cell receptor.
Victor H. Engelhard focuses on Immunology, Cancer research, T cell, Major histocompatibility complex and Cytotoxic T cell. The Cancer research study combines topics in areas such as Lymphatic system, Cancer immunotherapy, Immune system and Lymph. Within one scientific family, he focuses on topics pertaining to Antigen under T cell, and may sometimes address concerns connected to Cell culture.
In his research, Molecular biology is intimately related to Antigen presentation, which falls under the overarching field of Cell culture. He studies MHC class I, a branch of Major histocompatibility complex. His Cytotoxic T cell research includes themes of Ipilimumab, Viral vector, Naive T cell and Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
Donald F. Hunt;Robert A. Henderson;Jeffrey Shabanowitz;Kazuyasu Sakaguchi.
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
Andrea L. Cox;Jonathan Skipper;Ye Chen;Robert A. Henderson.
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation.
Robert A. Henderson;Hanspeter Michel;Kazuyasu Sakaguchi;Jeffrey Shabanowitz.
Cell-cell adhesion mediated by CD8 and MHC class I molecules.
Anne M. Norment;Russell D. Salter;Peter Parham;Victor H. Engelhard.
The minor histocompatibility antigen HA-1 : A diallelic gene with a single amino acid polymorphism
J. M. M. Den Haan;L. M. Meadows;Wei Wang;J. Pool.
Structure of Peptides Associated with Class I and Class II MHC Molecules
Victor H. Engelhard.
Annual Review of Immunology (1994)
Identification of a Graft-versus-Host Disease-associated human minor Histocompatibility antigen.
J M den Haan;N E Sherman;E Blokland;E Huczko.
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
J C Skipper;R C Hendrickson;P H Gulden;V Brichard.
Journal of Experimental Medicine (1996)
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells
Craig L. Slingluff;Gina R. Petroni;Galina V. Yamshchikov;Donna L. Barnd.
Journal of Clinical Oncology (2003)
The HLA-A^*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition
Leslie Meadows;Wei Wang;Joke M.M den Haan;Els Blokland.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: